Phase 1b/2 Trial of Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

This study is testing new combinations of medications to treat advanced skin cancer (melanoma) that has spread to the brain. Researchers want to see if these drugs can effectively stop cancer cells from growing in patients who have not responded well to previous immune-system treatments.

You may be eligible if you are at least 18 years old and have been diagnosed with melanoma that has spread to the brain. Your tumor must also have specific genetic markers (known as RAS, BRAF, or NF1 mutations) to see if these treatments will be a good fit for you.

Participants will take study medications—either a combination of two or three different drugs—designed to block signals that help cancer grow. You will have regular check-ups to monitor your health and ensure the treatment is being tolerated well by your body.

The study is currently recruiting patients at medical centers in Iowa City, Iowa, and Salt Lake City, Utah. If you are interested, your clinical team can help determine if a site near you is the right choice.